Drugs / Pazopanib
Pazopanib
also known as
GW786034 · Pazopanib Hydrochloride · Votrient · NSC-737754 · GW-786034B · NSC-752782 · paz · Pazopanib (as hydrochloride) · +8 more
Small molecule targets CSF1R, CYP2C8, CYP3A4, FGFR1, FGFR3, ITK, KIT, LCK, PDGFRA via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed primary peritoneal serous/papillary carcinoma 1 milestone | |||||
| Filed | EU (EMA) | Votrient | primary peritoneal serous/papillary carcinoma | 2013-08-07 | “today announced submission to the European Medicines Agency of a variation to the Marketing Authorisation for Votrient® (pazopanib)” gsk.com ↗ |
| Filed renal cell adenocarcinoma 1 milestone | |||||
| Filed | US (FDA) | — | renal cell adenocarcinoma | — | “completed the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for pazopanib” gsk.com ↗ |
| Filed soft tissue sarcoma 2 milestones | |||||
| Filed | EU (EMA) | Votrient | soft tissue sarcoma | 2011-07-06 | “submitted a variation to the Marketing Authorisation Application to the European Medicines Agency for Votrient (pazopanib)” gsk.com ↗ |
| Filed | US (FDA) | Votrient | soft tissue sarcoma | 2011-07-06 | “submitted a supplemental New Drug Application to the US Food and Drug Administration for Votrient” gsk.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (3) | US (FDA) | VOTRIENT | — | 2012-01-12 – 2014-11-18 | fda.gov ↗ |
| Approved | EU (EMA) | Votrient | — | 2010-06-14 | europa.eu ↗ |
| Approved | US (FDA) | VOTRIENT | — | 2009-10-19 | fda.gov ↗ |
Trials 242 · started per year
today
US approved 2009
EU approved 2010
1
1
4
13
14
14
13
37
36
35
13
10
19
7
7
2
2
1
2
2
4
3
1
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT02810756 | Sep 2016 → Aug 2017 | — | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 0 | NCT02729194 | Jun 2016 → Sep 2017 | renal cell carcinoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01221506 | Oct 2010 → Jun 2015 | renal cell carcinoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 161 trials · 1 missed | ||||||
| Phase 1 | NCT07444619 | Jun 2026 → Dec 2031 expected | soft tissue sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03139331 | Jun 2017 → Oct 2019 | sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT02795819 | Jul → Nov 2016 | metastatic neoplasm, renal cell carcinoma, soft tissue sarcoma | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 1 | NCT02406521 | Apr 2015 → Dec 2017 | renal cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02138526 | Jun 2014 → Nov 2018 | cancer | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02014636 | Dec 2013 → Feb 2019 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01639911 | Aug 2013 → Jul 2016 | breast cancer, central nervous system cancer, digestive system cancer, head and neck neoplasm +2 | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 1 | NCT01716416 | May 2013 → Jul 2015 | head and neck squamous cell carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01642017 | Nov 2012 → Sep 2017 | metastatic malignant neoplasm | Institut Claudius Regaud | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01713972 | Nov 2012 → Jul 2016 | cancer of unknown primary site | Manisha Shah | Completed | No outcome recorded |
| Phase 1 | NCT01542047 | Aug 2012 → Feb 2013 | metastatic malignant neoplasm | New Mexico Cancer Research Alliance | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01608009 | Jul 2012 → May 2015 | ovarian neoplasm | Imperial College London | Completed | No outcome recorded |
| Phase 1 | NCT01548144 | Apr 2012 → Aug 2021 | cancer of unknown primary site | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01552356 | Mar 2012 → Dec 2015 overdue | neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01472081 | Feb 2012 → Feb 2016 | clear cell renal carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01468922 | Jan 2012 → Sep 2014 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01413113 | Dec 2011 → Nov 2013 | thyroid gland follicular carcinoma, thyroid gland papillary carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT01485042 | Dec 2011 → Feb 2013 | cancer | Herbert Hurwitz, MD | Completed | No outcome recorded |
| Phase 1 | NCT01430572 | Oct 2011 → May 2020 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01454804 | Oct 2011 → Mar 2015 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01438554 | Oct 2011 → Apr 2016 | cholangiocarcinoma, soft tissue sarcoma, thyroid cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT01385228 | Jun 2011 → Jul 2015 | prostate cancer | Daniel George, MD | Completed | No outcome recorded |
| Phase 1 | NCT01339871 | Apr 2011 → Jun 2017 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01184326 | Jan 2011 → Mar 2017 | kidney cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01498458 | Oct 2010 → Dec 2011 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01407562 | Sep 2010 → Mar 2016 | cancer of unknown primary site, female breast carcinoma | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 1 | NCT01154062 | Aug 2010 → Apr 2011 | macular degeneration | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01202032 | Jul 2010 → Jan 2013 | refractory malignant neoplasm, renal cell carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1 | NCT01165385 | Jun 2010 → Oct 2013 | metastatic malignant neoplasm | UNICANCER | Completed | No outcome recorded |
| Phase 1 | NCT01985295 | Jun 2010 → Aug 2014 | soft tissue sarcoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01130623 | May 2010 → Nov 2011 | Wilms tumor, brain neoplasm, neuroblastoma, osteosarcoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT01072214 | Mar → Jun 2010 | macular degeneration | GlaxoSmithKline | Completed | Missed primary |
| Phase 1 | NCT01060514 | Feb 2010 → Feb 2012 | breast cancer, non-small cell lung carcinoma | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01072890 | Feb 2010 → Feb 2012 | cancer | University of California, Davis | Completed | No outcome recorded |
| Phase 1 | NCT01051700 | Jan → May 2010 | macular degeneration | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01012362 | Dec 2009 → Feb 2013 | breast cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma +4 | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT00992121 | Nov 2009 → Nov 2013 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00866528 | Jul 2009 → Oct 2012 | non-small cell lung carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00929903 | Jun 2009 → Apr 2013 | central nervous system teratoma, childhood brain stem glioma, childhood central nervous system germinoma, childhood central nervous system mixed germ cell tumor +4 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00800345 | Apr 2009 → Jun 2015 | female reproductive system neoplasm | Vector Oncology | Completed | No outcome recorded |
| Phase 1 | NCT00861029 | Mar 2009 → Feb 2010 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00674024 | Oct 2008 → Jan 2013 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00722293 | Jul 2008 → Jun 2012 | breast neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00659555 | Apr → May 2008 | macular degeneration | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00678977 | Apr 2008 → Mar 2010 | non-small cell lung carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00619424 | Nov 2007 → Sep 2009 | non-small cell lung carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00516672 | Sep 2007 → Aug 2010 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00478725 | Jul 2007 → Jul 2008 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00540943 | Jul 2007 → May 2010 | colorectal cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00463320 | Mar → Aug 2007 | age-related macular degeneration | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00450879 | Jan 2007 → Nov 2010 | male breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00370513 | Dec 2006 → Apr 2009 | hepatocellular carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00387387 | Oct 2006 → Aug 2009 | colorectal neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00363194 | Sep 2006 → Jun 2009 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00401583 | Jul 2006 → Feb 2008 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00387205 | Jun 2006 → Feb 2013 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00388076 | Apr 2006 → Jul 2009 | breast neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00358384 | Sep 2005 → Feb 2006 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00158782 | Sep 2004 → Aug 2007 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00060151 | Dec 2002 → Jun 2009 | cancer of unknown primary site | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00788580 | — | cancer of unknown primary site | SWOG Cancer Research Network | Withdrawn | No outcome recorded |
| Phase 1/222 trials · 1 missed | ||||||
| Phase 1/2 | NCT06895733 | Nov 2024 → Dec 2025 overdue | cancer | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06239272 | Mar 2024 → Jun 2034 expected | angiosarcoma, extraosseous osteosarcoma, fibrosarcoma, histiocytoma, Angiomatoid fibrous +3 | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03850730 | Jul 2023 → Jun 2025 | hereditary hemorrhagic telangiectasia | Cure HHT | Unknown | No outcome recorded |
| Phase 1/2 | NCT05210413 | May 2022 → Aug 2025 overdue | refractory malignant neoplasm | University Hospital, Bordeaux | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05180695 | Apr 2022 → Feb 2027 expected | soft tissue sarcoma | Centre Leon Berard | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03660930 | Apr 2019 → Nov 2022 | soft tissue sarcoma | University of Washington | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02601209 | Nov 2015 → Dec 2018 | leiomyosarcoma of the corpus uteri, malignant peripheral nerve sheath tumor, myxofibrosarcoma, synovial sarcoma +1 | National Cancer Institute (NCI) | Terminated | Missed primary |
| Phase 1/2 | NCT02331498 | Jun 2015 → Feb 2027 expected | glioblastoma | Centre Antoine Lacassagne | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02303028 | Mar 2015 → Jun 2022 | cancer | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 1/2 | NCT02055690 | Sep 2014 → Nov 2017 | ovarian cancer | The Christie NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 1/2 | NCT01684397 | Nov 2012 → Aug 2026 overdue | clear cell renal carcinoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01719302 | Oct 2012 → Apr 2015 | soft tissue sarcoma | University of Vermont | Completed | No outcome recorded |
| Phase 1/2 | NCT01402271 | Jul 2012 → May 2019 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1/2 | NCT01600573 | May 2012 → Mar 2017 | ovarian cancer | JSehouli | Unknown | No outcome recorded |
| Phase 1/2 | NCT01465659 | Dec 2011 → Jul 2018 | pancreatic delta cell neuroendocrine tumor, pancreatic endocrine carcinoma, pancreatic gastrin-producing neuroendocrine tumor, pancreatic insulin-producing neuroendocrine tumor | Northwestern University | Completed | No outcome recorded |
| Phase 1/2 | NCT01418001 | Aug 2011 → Nov 2015 | leiomyosarcoma, malignant peripheral nerve sheath tumor, undifferentiated pleomorphic sarcoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01513187 | Jul 2011 → Dec 2015 | renal cell carcinoma | Spanish Oncology Genito-Urinary Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01716546 | Jul 2011 → Jan 2015 | gastric cancer | Hellenic Oncology Research Group | Terminated | No outcome recorded |
| Phase 1/2 | NCT01265940 | Mar 2011 → Jan 2012 | urothelial carcinoma | Prof. Dr. Thomas Otto | Completed | No outcome recorded |
| Phase 1/2 | NCT01257750 | Nov 2010 → Jan 2012 | corneal neovascularization | Reza Dana, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01238770 | Nov 2010 → Oct 2014 | malignant epithelial tumor of ovary | Priv.-Doz. Dr. med. Joachim Rom | Completed | No outcome recorded |
| Phase 1/2 | NCT01035658 | Jan 2010 → Jun 2012 | fallopian tube cancer, ovarian cancer, peritoneal carcinoma | SCRI Development Innovations, LLC | Terminated | No outcome recorded |
| Phase 2129 trials · 8 met primary · 16 missed | ||||||
| Phase 2 | NCT07087158 | Sep 2025 → Dec 2026 expected | renal cell carcinoma | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06816771 | Feb → Dec 2025 overdue | rhabdomyosarcoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06739395 | Nov 2024 → Dec 2026 expected | cancer | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05679921 | Mar 2024 → Dec 2026 expected | soft tissue sarcoma | Yonsei University | Recruiting | No outcome recorded |
| Phase 2 | NCT02645149 | Nov 2021 → Nov 2025 | melanoma | Melanoma Institute Australia | Completed | No outcome recorded |
| Phase 2 | NCT03798106 | Apr 2019 → Aug 2022 | sarcoma | Yonsei University | Completed | Met primary |
| Phase 2 | NCT03334409 | Feb 2018 → Mar 2021 | clear cell renal carcinoma | Academic and Community Cancer Research United | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT03200717 | Nov 2017 → Aug 2021 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03149120 | Aug 2017 | soft tissue sarcoma | NYU Langone Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02960906 | May 2017 → Feb 2021 | clear cell renal carcinoma | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Completed | No outcome recorded |
| Show all 129 trials opens the full record — a long page | ||||||
| Phase 2/34 trials · 2 met primary | ||||||
| Phase 2/3 | NCT03850964 | May 2023 → Nov 2025 overdue | anemia, hereditary hemorrhagic telangiectasia | Cure HHT | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02180867 | Aug 2014 → Jun 2019 | alveolar soft part sarcoma, clear cell sarcoma, cutaneous undifferentiated pleomorphic sarcoma, epithelioid malignant peripheral nerve sheath tumor +19 | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 2/3 | NCT01208064 | Jul 2011 → Jun 2015 | lung cancer | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 2/3 | NCT00775307 | Nov 2008 → Dec 2015 | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Completed | Met primary |
| Phase 311 trials · 5 met primary · 4 missed | ||||||
| Phase 3 | NCT02979899 | Feb 2017 → Apr 2019 | angiosarcoma | Tracon Pharmaceuticals Inc. | Completed | Missed primary |
| Phase 3 | NCT02535351 | Nov 2015 → Sep 2018 | clear cell renal carcinoma | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Terminated | No outcome recorded |
| Phase 3 | NCT01575548 | Aug 2012 → Jul 2018 overdue | clear cell renal carcinoma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT01613846 | May 2012 → Oct 2016 | renal cell carcinoma | Technical University of Munich | Completed | Missed primary |
| Phase 3 | NCT01235962 | Nov 2010 → Oct 2015 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT01064310 | May 2010 → Oct 2011 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00866697 | May 2009 → Jul 2012 | ovarian carcinoma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00753688 | Oct 2008 → Nov 2010 | soft tissue sarcoma | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00720941 | Aug 2008 → May 2012 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00387764 | Sep 2006 → Dec 2009 | renal cell carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00334282 | Apr 2006 → May 2008 | renal cell carcinoma | GlaxoSmithKline | Completed | Met primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT03735758 | Nov 2018 → Oct 2020 | soft tissue sarcoma | GWT-TUD GmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02570789 | Dec 2012 → Dec 2018 | clear cell renal carcinoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01521715 | Jan 2012 → Jun 2017 | clear cell renal carcinoma | iOMEDICO AG | Completed | No outcome recorded |
| Phase 4 | NCT01205230 | Sep 2010 → Aug 2011 | cancer | GlaxoSmithKline | Completed | Mixed |
| Phase not applicable8 trials · 1 missed | ||||||
| — | NCT04199026 | Feb 2025 → Dec 2028 expected | sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| — | NCT02691767 | May 2016 → Jan 2018 | refractory malignant neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT02450136 | Oct 2015 → Jul 2017 | refractory malignant neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02307474 | Sep 2015 | clear cell renal carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| — | NCT01599832 | Jun 2012 → Dec 2015 | clear cell renal carcinoma | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01446809 | Apr 2012 → Jan 2019 | soft tissue sarcoma | University of Washington | Completed | Missed primary |
| — | NCT01636908 | Aug 2011 → Jan 2018 | cancer | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Comparator or background therapy25 trials | ||||||
| Phase 1 | NCT03275558 Comparator | Jul 2018 | gliosarcoma | Center Trials & Treatment | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02009449 Background | Nov 2013 → Feb 2019 | breast cancer, colorectal carcinoma, melanoma, non-small cell lung carcinoma +3 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00732420 Background | Sep 2008 → Jun 2013 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT03628131 Background | Oct 2018 → Jul 2023 | childhood malignant neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT01975519 Background | Dec 2013 → Mar 2019 | soft tissue sarcoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02203760 Comparator | Oct 2019 → Dec 2024 overdue | female reproductive organ cancer | North Eastern German Society of Gynaecological Oncology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02959554 Comparator | Dec 2016 → Aug 2020 | renal cell carcinoma | AIO-Studien-gGmbH | Terminated | No outcome recorded |
| Phase 2 | NCT03379012 Background | Feb 2016 → Jan 2018 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 2 | NCT02207309 Comparator | Jun 2015 → Jul 2016 | soft tissue sarcoma | Ludwig-Maximilians - University of Munich | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02187302 Comparator | Jul 2014 → Jul 2016 | renal cell carcinoma | NewLink Genetics Corporation | Completed | Missed primary |
| Phase 2 | NCT01813136 Comparator | Mar 2013 → Jan 2019 | thyroid gland carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT00430781 Comparator | Nov 2006 → Jul 2008 | cervical cancer | GlaxoSmithKline | Completed | Mixed |
| Phase 2/3 | NCT05432791 Comparator | Mar 2023 → Aug 2024 overdue | leiomyosarcoma of the corpus uteri | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06726421 Background | Sep 2024 → Sep 2030 expected | renal cell carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06263231 Comparator | Jun 2024 → Dec 2027 expected | soft tissue sarcoma | Intensity Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04741438 Comparator | Mar 2021 → Feb 2025 | sarcoma | Centre Leon Berard | Unknown | No outcome recorded |
| Phase 3 | NCT03592472 Background | Jul 2018 → Dec 2026 expected | renal cell carcinoma | Xynomic Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03260894 Comparator | Dec 2017 → Aug 2018 | renal cell carcinoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02049905 Comparator | Jan 2014 → May 2017 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05949424 Comparator | May 2024 → Mar 2025 | breast carcinoma, endometrial carcinoma, ovarian carcinoma, renal cell carcinoma +1 | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 4 | NCT02555748 Comparator | Nov 2015 → Jan 2020 | renal cell carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| — | NCT05816642 Comparator | Aug 2022 → Dec 2023 | renal cell carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03571438 Comparator | Oct 2017 → Sep 2022 | kidney cancer | University Hospital, Grenoble | Unknown | No outcome recorded |
| — | NCT02208128 Comparator | May 2014 → Feb 2018 | renal cell carcinoma | Heidelberg University | Unknown | No outcome recorded |
| — | NCT02354612 Background | — | cancer | Tracon Pharmaceuticals Inc. | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2020-03-26 | Alvogen Korea | Regulatory Alvogen submits European application for generic Pazopanib alvogen.com ↗
Alvogen today announced that it has submitted generic dossier applications for Pazopanib tablets. |
| 2014-04-01 | GlaxoSmithKline | Results Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology gsk.com ↗
The results showed that 70% (95%* CI, 60.9–78.4) of patients expressed a preference for pazopanib compared to 22% (95%* CI, 14.7–30.6) expressing a preference for sunitinib, as assessed by a questionnaire. |
| 2014-03-31 | GlaxoSmithKline | Regulatory Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU gsk.com ↗
Issued: London UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorisation for Votrient® (pazopanib). |
| 2013-08-07 | GlaxoSmithKline | Regulatory Regulatory Update - GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer gsk.com ↗
This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline. |
| 2013-06-01 | GlaxoSmithKline | Results GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer gsk.com ↗
GlaxoSmithKline (GSK) plc today announced that its Phase III clinical trial of VOTRIENT (pazopanib) as maintenance therapy in women with advanced epithelial ovarian cancer following front-line chemotherapy met the primary objective of a statistically significant improvement in the time to disease progression or death (progression-free survival, PFS) compared to placebo. |
| 2012-08-07 | GlaxoSmithKline | Regulatory European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes gsk.com ↗
GlaxoSmithKline plc announced today that the European Commission has granted pazopanib marketing authorisation for the treatment of patients with advanced soft tissue sarcoma (aSTS) who have received prior chemotherapy or have progressed within 12 months after (neo) adjuvant therapy. |
| 2012-05-25 | GlaxoSmithKline | Regulatory GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas gsk.com ↗
the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Votrient® (pazopanib) |
| 2012-04-26 | GlaxoSmithKline | Regulatory FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma gsk.com ↗
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy. |
| 2012-03-20 | GlaxoSmithKline | Regulatory GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas gsk.com ↗
the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient |
| 2011-07-06 | GlaxoSmithKline | Regulatory EU and US Regulatory Update - Votrient® (pazopanib) gsk.com ↗
Additionally, GSK announced that it has submitted a supplemental New Drug Application to the US Food and Drug Administration for Votrient for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy. |
| 2011-06-04 | GlaxoSmithKline | Results GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas gsk.com ↗
Results of the PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant improvement in the time to first occurrence of tumour progression or death (progression free survival or PFS) for study patients treated with the multi-tyrosine kinase inhibitor pazopanib, compared to placebo. |
| 2010-06-14 | GlaxoSmithKline | Regulatory GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib) gsk.com ↗
GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a conditional marketing authorisation for Votrient® (pazopanib) for the first-line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. |
| 2010-02-18 | GlaxoSmithKline | Regulatory GSK receives positive opinions in Europe for Tyverb® (lapatinib) and Votrient™ (pazopanib) gsk.com ↗
The CHMP has also recommended the conditional marketing authorisation for VotrientTM (pazopanib), for the first-line treatment of advanced RCC and for patients who have received prior cytokine therapy for advanced disease. |
| 2009-10-19 | GlaxoSmithKline | Regulatory FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer gsk.com ↗
GlaxoSmithKline [NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient™ (pazopanib) to treat patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. |
| 2009-10-05 | GlaxoSmithKline | Regulatory GlaxoSmithKline receives unanimous FDA Panel approval recommendation for Votrient™ gsk.com ↗
GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of Votrient™ (pazopanib). |
| 2009-05-31 | GlaxoSmithKline | Results GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer gsk.com ↗
Today, GlaxoSmithKline announced the results of a Phase III study demonstrating that pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo. |
| 2009-03-04 | GlaxoSmithKline | Regulatory GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer gsk.com ↗
GlaxoSmithKline (GSK) today announced the submission of a Marketing Authorisation Application (MAA) tothe European Medicines Agency (EMEA) for pazopanib as an oral therapy for patients with advanced and/or metastatic renal cell carcinoma (RCC). |
All press releases naming this drug 19 releases
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 274 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pazopanib | “GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2,...” NCT00158782 ↗262“Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 ↗ Nov 2017 “Pazopanib is an oral chemotherapy and works by decreasing the blood supply to tumors which limits the tumor's source of oxygen and nutrients.” NCT01622660 ↗ “Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma” NCT00256880 ↗ “pazopanib hydrochloride (pazopanib)” NCT01664182 ↗ “Paclitaxel, Pazopanib, Pentostatin” NCT02788201 ↗ “Sunitinib, Sorafenib or Pazopanib” NCT01731158 ↗ “Paclitaxel Pazopanib Pentostatin” NCT02551718 ↗ “GW786034 (pazopanib)” NCT00401583 ↗ “KIT - Pazopanib” NCT02645149 ↗ |
| Known as | GW-786034B | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | GW786034 | “A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects With Stage IA, IB, IIA or...” NCT00367679 ↗33“A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma included 19 patients after a maximum of 2 lines of chemotherapy for...” NCT01498458 ↗ “Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-alpha, PDGFR-beta...” PMID 18230058 ↗ Feb 2008 “I. To establish the safety and efficacy of GW786034 (pazopanib hydrochloride) as a therapeutic in patients afflicted with differentiated, medullary and anaplastic thyroid cancers.” NCT00625846 ↗ “The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.” PMID 22014006 ↗ Oct 2011 “Pilot Study of GW786034 (Pazopanib), a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Operable Breast Cancer” NCT00450879 ↗ “A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy” NCT00454571 ↗ “Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma” PMID 20200024 ↗ Mar 2010 “A Phase 2 Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer” NCT00486642 ↗ “Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients” NCT00861913 ↗ “Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma” NCT00334282 ↗ |
| Known as | NSC-737754 | “A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors” NCT01956669 ↗1“GW786034 (Pazopanib; NSC-737754; IND-XXXX)” NCT00788580 ↗ |
| Known as | NSC-752782 | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | paz | “Pazopanib (paz) is a potent small molecular inhibitor of VEGF-1, -2, -3, PDGFR, c-kit, and has activity as a single agent in ovarian cancer.” PMID 32247603 ↗ Apr 2020 |
| Known as | Pazopanib (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | Pazopanib (GW786034) | “Pazopanib (GW786034)” NCT01385228 ↗ |
| Known as | Pazopanib (GW786034; Votrient) | “Pazopanib (GW786034; Votrient®)” NCT01577784 ↗ |
| Known as | Pazopanib hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | Pazopanib Hydrochloride | “To assess the safety and tolerability of GSK2118436 (dabrafenib) given with pazopanib (pazopanib hydrochloride) as well as determining the maximum tolerated dosing regimen in...” NCT01713972 ↗22“The purpose of this study is to find out what effects pazopanib (pazopanib hydrochloride) (also called Votrient®) may have on MRI (magnetic resonance imaging) scans, blood...” NCT01599832 ↗ “I. To establish the safety and efficacy of GW786034 (pazopanib hydrochloride) as a therapeutic in patients afflicted with differentiated, medullary and anaplastic thyroid cancers.” NCT00625846 ↗ “Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.” NCT01402271 ↗ “Determine the maximum tolerated dose (MTD) of temozolomide and pazopanib (pazopanib hydrochloride) combination in patients with advanced PNET.” NCT01465659 ↗ “This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma.” NCT01462630 ↗ “Giving pazopanib hydrochloride together with bicalutamide may be an effective treatment for prostate cancer.” NCT00486642 ↗ “pazopanib (pazopanib hydrochloride) as 3rd-line therapy in metastatic renal cell carcinoma (mRCC) patients” NCT01157091 ↗ “pazopanib (pazopanib hydrochloride) plus oral topotecan (topotecan hydrochloride).” NCT02357810 ↗ “daily oral GW786034 (pazopanib hydrochloride) for at least 12 consecutive days” NCT00450879 ↗ “Patients receive oral pazopanib hydrochloride once daily on days 1-28.” NCT00471536 ↗ |
| Known as | Pazopanib is marketed as Votrient. | “Pazopanib is marketed as Votrient.” NCT01265940 ↗ |
| Known as | Pazopanib monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | Pazopanib monohydrochloride salt GW786034 | “Pazopanib monohydrochloride salt GW786034” NCT01049776 ↗ |
| Known as | PZP | “Association of Bevacizumab (BVC)+ Pazopanib (PZP)” NCT01202032 ↗ |
| Known as | Votrient | “The patient was enrolled in a clinical trial and treated with an anaplastic lymphoma kinase (ALK) inhibitor (crizotinib/Xalkori®) and a multikinase VEGF inhibitor (pazopanib/Votrient®).” PMID 26062823 ↗ Jun 20154“The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere).” NCT01593748 ↗ “Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL)” NCT00388076 ↗ “Pazopanib Oral Tablet [Votrient]” NCT04741438 ↗ |
| Known as | Votrient (Pazopanib hydrochloride) | “Votrient (Pazopanib hydrochloride)” NCT01472081 ↗ |
| Action | Inhibit | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL477772 ↗5“Fibroblast growth factor receptor 3 inhibitor” CHEMBL477772 ↗ “Fibroblast growth factor receptor 1 inhibitor” CHEMBL477772 ↗ “Tyrosine-protein kinase ITK/TSK inhibitor” CHEMBL477772 ↗ “Tyrosine-protein kinase LCK inhibitor” CHEMBL477772 ↗ “tyrosine kinase inhibitor” NCT00158782 ↗ |
| Modality | Small molecule | “small molecule” NCT00158782 ↗ |
| Route | Oral | “Patients receive oral GW786034 twice daily.” NCT00060151 ↗ |
| Target | CSF1R | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL477772 ↗ |
| Target | CYP2C8 | “pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4” PMID 24800949 ↗ May 2014 |
| Target | CYP3A4 | “pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4” PMID 24800949 ↗ May 2014 |
| Target | FGFR1 | “Fibroblast growth factor receptor 1 inhibitor” CHEMBL477772 ↗ |
| Target | FGFR3 | “Fibroblast growth factor receptor 3 inhibitor” CHEMBL477772 ↗ |
| Target | ITK | “Tyrosine-protein kinase ITK/TSK inhibitor” CHEMBL477772 ↗ |
| Target | LCK | “Tyrosine-protein kinase LCK inhibitor” CHEMBL477772 ↗ |